Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by DOSTAL, L. A.
Right arrow Articles by ANDERSON, J. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by DOSTAL, L. A.
Right arrow Articles by ANDERSON, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1991 Oxford University Press

research-article

Fertility and Perinatal/Postnatal Studies in Rats with the Angiotensin-Converting Enzyme Inhibitor, Quinapril

LORI A. DOSTAL*,1, SANG-NAM KIM*, JAMES L. SCHARDEIN{dagger} and JOHN A. ANDERSON*

*Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company 2800 Plymouth Road, Ann Arbor, Michigan 48105 {dagger}International Research and Development Corporation Mattawan, Michigan 49071

Received March 18, 1991; accepted May 29, 1991

Fertility and Perinatal/Postnatal Studies in Rats with the Angiotensin-Converting Enzyme Inhibitor, Quinapril. DOSTAL, L. A., KIM, S-N., SCHARDEIN, J. L., AND ANDERSON, J. A. (1991). Fundam. Appl. Toxicol. 17, 684–695. Quinapril, an inhibitor of angiotensin-converting enzyme (ACE) and an antihypertensive agent, was evaluated in rats for effects on fertility, reproduction, and perinatal and postnatal development In a fertility study, male rats were treated by gavage for 60 days prior to and during mating and female rats were treated by gavage for 14 days prior to mating, during mating and gestation, and during lactation with doses of 0, 10, 50, or 100 mg quinapril/kg body wt There were no significant effects on body weight, food consumption, fertility indices, fetal development, or neonatal growth, survival, development, behavior, or reproduction. In a perinatal/postnatal study, administration of quinapril to females at doses of 25, 75, or 150 mg/kg during late gestation and lactation had no effects on parturition, lactation, or postnatal development, but a significant decrease in neonatal body weight during the suckling period was observed at all doses. In a subsequent study, female rats were given 150 mg/kg during late gestation, lactation, or late gestation and lactation. No adverse effects were seen in the dams or the offspring, and no reduction in neonatal body weight was observed. Kidneys from pups whose mothers received quinapril during gestation and/or lactation had minimal juxtaglomerular cell hypertrophy, characteristic of treatment with ACE inhibitors. Low levels of quinaprilat (the major and pharmacologically active metabolite of quinapril) were detected in fetal blood and in neonatal blood, indicating offspring exposure to quinapril. Milk quinaprilat concentrations were 3–5% of the plasma concentrations 3–5 hr after dosing. These studies demonstrate no adverse effects of quinapril on fertility, reproduction, or perinatal and postnatal development.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.